Exoskeleton-Assisted Physical Therapy Systems: Accelerating Recovery & Market Growth in 2025–2030
···

Exoskeleton-Assisted Physical Therapy Systems: Accelerating Recovery & Market Growth in 2025–2030

May 23, 2025
by

How Exoskeleton-Assisted Physical Therapy Systems Are Revolutionizing Rehabilitation in 2025: Market Dynamics, Breakthrough Technologies, and the Road Ahead

Executive Summary: 2025 Market Snapshot & Key Takeaways

The global market for exoskeleton-assisted physical therapy systems is poised for significant growth in 2025, driven by technological advancements, increasing clinical adoption, and expanding reimbursement frameworks. Exoskeletons—wearable robotic devices designed to support or enhance limb movement—are increasingly integrated into rehabilitation protocols for patients recovering from stroke, spinal cord injuries, and other neuromuscular conditions. In 2025, the sector is characterized by a shift from pilot programs and research trials to broader clinical deployment, particularly in North America, Europe, and parts of Asia.

Key industry leaders such as Ekso Bionics, ReWalk Robotics, and CYBERDYNE Inc. continue to expand their product portfolios and global reach. Ekso Bionics has reported increased adoption of its EksoNR exoskeleton in rehabilitation centers, with clinical data supporting improved patient outcomes in gait training and neurorehabilitation. ReWalk Robotics has focused on both personal and clinical exoskeletons, with regulatory clearances in the US and Europe facilitating wider access. Japanese innovator CYBERDYNE Inc. has seen its HAL (Hybrid Assistive Limb) system deployed in hospitals and rehabilitation facilities across Asia and Europe, with ongoing studies demonstrating efficacy in motor function recovery.

In 2025, the market is also witnessing the entry of new players and the introduction of lighter, more user-friendly exoskeletons. Companies such as BIONIK Laboratories and SuitX (now part of Ottobock) are contributing to the diversification of available solutions, targeting both upper and lower limb rehabilitation. The integration of artificial intelligence and real-time data analytics is enhancing device adaptability and personalized therapy, a trend expected to accelerate over the next few years.

Reimbursement remains a critical factor for market expansion. In 2025, several countries have initiated or expanded insurance coverage for exoskeleton-assisted therapy, particularly for spinal cord injury and stroke rehabilitation. This policy evolution is expected to drive further adoption in clinical settings and, eventually, in home-based care.

Looking ahead, the exoskeleton-assisted physical therapy systems market is projected to maintain double-digit growth rates through the late 2020s. Key takeaways for 2025 include: rapid technological innovation, growing clinical validation, expanding reimbursement, and increasing global competition. The sector is transitioning from early adoption to mainstream integration, with a strong outlook for improved patient mobility and quality of life.

Market Size, Growth Rate, and Forecasts Through 2030

The global market for exoskeleton-assisted physical therapy systems is experiencing robust growth, driven by technological advancements, increasing prevalence of neurological and musculoskeletal disorders, and a rising demand for innovative rehabilitation solutions. As of 2025, the market is estimated to be valued in the low-to-mid single-digit billions (USD), with projections indicating a compound annual growth rate (CAGR) exceeding 15% through 2030. This expansion is fueled by both the clinical adoption of exoskeletons in rehabilitation centers and the growing interest in home-based therapy solutions.

Key industry players are actively shaping the market landscape. ReWalk Robotics, a pioneer in wearable robotic exoskeletons, continues to expand its presence in North America, Europe, and Asia, reporting increased installations in rehabilitation clinics and hospitals. Ekso Bionics has also seen significant growth, with its EksoNR system being adopted by leading rehabilitation facilities for stroke and spinal cord injury patients. CYBERDYNE Inc., based in Japan, is advancing the use of its HAL (Hybrid Assistive Limb) exoskeleton in both clinical and home settings, supported by regulatory approvals and insurance coverage in select markets.

The market is further bolstered by the entry of new players and the expansion of established medical device companies into the exoskeleton segment. Hocoma, known for its robotic rehabilitation solutions, is integrating exoskeleton technology into its product portfolio, while Ottobock is leveraging its expertise in prosthetics and orthotics to develop advanced exoskeletons for therapy and mobility assistance.

Geographically, North America and Europe remain the largest markets, driven by high healthcare expenditure, favorable reimbursement policies, and a strong network of rehabilitation centers. However, Asia-Pacific is expected to witness the fastest growth through 2030, propelled by increasing investments in healthcare infrastructure, rising awareness, and supportive government initiatives, particularly in countries like Japan, South Korea, and China.

Looking ahead, the exoskeleton-assisted physical therapy systems market is poised for continued expansion. Key trends shaping the outlook include the miniaturization and cost reduction of exoskeleton devices, integration of artificial intelligence for personalized therapy, and the development of lightweight, user-friendly systems suitable for home use. As clinical evidence supporting the efficacy of exoskeleton-assisted rehabilitation grows, adoption rates are expected to accelerate, positioning the sector for sustained double-digit growth through the end of the decade.

Key Players and Industry Ecosystem (e.g., eksoBionics.com, rewalk.com, suitx.com)

The exoskeleton-assisted physical therapy systems sector is rapidly evolving, with several pioneering companies shaping the industry landscape as of 2025. These organizations are driving innovation in wearable robotics, targeting rehabilitation for patients with neurological and musculoskeletal impairments. The industry ecosystem is characterized by a blend of established medical device manufacturers, specialized robotics firms, and collaborative partnerships with healthcare providers and research institutions.

Among the most prominent players is Ekso Bionics, a California-based company recognized for its FDA-cleared EksoNR exoskeleton. EksoNR is designed for use in rehabilitation centers to assist patients recovering from stroke, spinal cord injury, and acquired brain injury. The system provides adaptive assistance and real-time feedback, enabling therapists to tailor therapy sessions and track patient progress. Ekso Bionics has expanded its global footprint through partnerships with leading hospitals and rehabilitation centers, and continues to invest in clinical research to validate the efficacy of its solutions.

Another key innovator is ReWalk Robotics, headquartered in Israel and the United States. ReWalk’s exoskeletons are FDA-cleared for both personal and clinical use, with the ReWalk Personal 6.0 system allowing individuals with lower limb disabilities to walk independently. The company has also introduced the ReStore soft exosuit, targeting gait training for stroke survivors. ReWalk maintains collaborations with rehabilitation networks and insurance providers to improve accessibility and reimbursement for its devices.

A notable competitor, SuitX (now part of Ottobock), has developed modular exoskeletons such as the Phoenix, which is lightweight and designed for mobility-impaired users. SuitX’s integration into Ottobock, a global leader in prosthetics and orthotics, has accelerated the commercialization and distribution of exoskeleton technologies worldwide. Ottobock’s extensive clinical network and expertise in assistive devices position it as a major force in the exoskeleton therapy market.

Other significant contributors include CYBERDYNE Inc. of Japan, known for its HAL (Hybrid Assistive Limb) exoskeleton, which is widely used in rehabilitation settings across Asia and Europe. Hocoma, a Swiss company, integrates robotic exoskeletons into comprehensive neurorehabilitation platforms, often in partnership with research hospitals.

Looking ahead, the industry is expected to see increased collaboration between exoskeleton manufacturers, healthcare providers, and digital health companies. Integration of artificial intelligence, cloud-based data analytics, and tele-rehabilitation features is anticipated to enhance patient outcomes and expand the reach of exoskeleton-assisted therapy. As regulatory approvals broaden and reimbursement pathways improve, the adoption of these systems in clinical and home settings is projected to accelerate through the late 2020s.

Technological Innovations: Robotics, AI, and Sensor Integration

Exoskeleton-assisted physical therapy systems are at the forefront of technological innovation in rehabilitation, leveraging advancements in robotics, artificial intelligence (AI), and sensor integration to enhance patient outcomes. As of 2025, these systems are increasingly being adopted in clinical and home settings, driven by the need for more effective, personalized, and data-driven rehabilitation solutions.

Robotic exoskeletons, such as those developed by Ekso Bionics and ReWalk Robotics, are designed to assist individuals with mobility impairments resulting from conditions like stroke, spinal cord injury, or multiple sclerosis. These devices provide powered assistance for walking and movement, enabling repetitive, task-specific training that is critical for neuroplasticity and functional recovery. Recent models incorporate lightweight materials and ergonomic designs, improving comfort and usability for both patients and therapists.

AI integration is a key trend shaping the next generation of exoskeletons. By analyzing real-time data from embedded sensors, AI algorithms can adapt assistance levels to the user’s capabilities and progress, optimizing therapy intensity and duration. For example, CYBERDYNE Inc.’s HAL exoskeleton uses bioelectrical signal detection to interpret the wearer’s movement intentions, allowing for more natural and responsive support. This approach not only enhances patient engagement but also provides clinicians with objective metrics to track rehabilitation progress.

Sensor technology is another critical component, with modern exoskeletons featuring arrays of inertial measurement units (IMUs), force sensors, and electromyography (EMG) sensors. These sensors capture detailed biomechanical and physiological data, enabling precise monitoring of gait patterns, muscle activation, and joint angles. Companies like Ottobock are integrating advanced sensor suites into their exoskeletons to facilitate real-time feedback and remote monitoring, supporting tele-rehabilitation and expanding access to therapy.

Looking ahead, the outlook for exoskeleton-assisted physical therapy systems is highly promising. Ongoing research and development are focused on increasing device autonomy, reducing costs, and expanding indications for use. Collaborations between manufacturers, healthcare providers, and research institutions are expected to accelerate the translation of laboratory innovations into clinical practice. As regulatory pathways become clearer and reimbursement models evolve, adoption rates are projected to rise, making exoskeleton-assisted therapy a standard component of neurorehabilitation programs worldwide.

Clinical Applications: Neurological, Orthopedic, and Geriatric Rehabilitation

Exoskeleton-assisted physical therapy systems are rapidly transforming clinical rehabilitation for neurological, orthopedic, and geriatric populations. As of 2025, these wearable robotic devices are increasingly integrated into hospital and outpatient settings, offering new avenues for restoring mobility, strength, and independence in patients with diverse impairments.

In neurological rehabilitation, exoskeletons are most prominently used for patients recovering from stroke, spinal cord injury, and traumatic brain injury. Devices such as the Ekso Bionics EksoNR and ReWalk Robotics ReWalk Personal 6.0 enable overground gait training, providing repetitive, task-specific movement that is critical for neuroplasticity and functional recovery. Clinical studies and real-world deployments have shown that exoskeleton-assisted therapy can improve walking speed, endurance, and lower limb strength, with some patients achieving partial or full ambulation after intensive training. In 2024 and 2025, several rehabilitation centers in North America, Europe, and Asia have expanded their exoskeleton fleets, citing improved patient outcomes and increased therapy efficiency.

Orthopedic rehabilitation is another area where exoskeletons are gaining traction, particularly for post-surgical recovery (e.g., after joint replacement or fracture repair) and musculoskeletal injuries. Companies like CYBERDYNE Inc. have developed devices such as the HAL (Hybrid Assistive Limb) that support both voluntary and assisted movement, allowing patients to safely regain mobility while reducing the risk of secondary injuries. These systems are being adopted in specialized orthopedic clinics and sports medicine centers, with early data suggesting faster recovery times and reduced therapist workload.

Geriatric rehabilitation represents a significant growth area, as aging populations drive demand for solutions that address age-related mobility decline and fall risk. Exoskeletons tailored for elderly users, such as the SuitX (now part of Ottobock) Phoenix, are designed for ease of use, lightweight construction, and adjustable support levels. These systems are being piloted in long-term care facilities and community-based programs, with the goal of maintaining independence and reducing healthcare costs associated with immobility and falls.

Looking ahead, the next few years are expected to bring further advances in exoskeleton technology, including improved sensor integration, adaptive control algorithms, and greater customization for individual patient needs. Regulatory approvals and reimbursement pathways are also expanding, with several devices receiving CE marking and FDA clearance for clinical use. As exoskeletons become more affordable and accessible, their role in multidisciplinary rehabilitation is set to grow, offering hope for enhanced recovery and quality of life across neurological, orthopedic, and geriatric populations.

The regulatory landscape for exoskeleton-assisted physical therapy systems is evolving rapidly as these devices become more prevalent in clinical and rehabilitation settings. In 2025, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to refine their frameworks to address the unique safety, efficacy, and performance considerations of wearable robotic exoskeletons. In the United States, exoskeletons intended for medical rehabilitation are generally classified as Class II medical devices, requiring 510(k) premarket notification. Companies like Ekso Bionics and ReWalk Robotics have successfully navigated this process, with their devices receiving FDA clearances for use in rehabilitation of patients with spinal cord injury and stroke.

In Europe, exoskeletons are regulated under the Medical Device Regulation (MDR), which came fully into effect in 2021 and continues to impact market access in 2025. The MDR imposes stricter requirements for clinical evidence and post-market surveillance, prompting manufacturers to invest in robust clinical trials and real-world data collection. Companies such as CYBERDYNE Inc., known for its HAL (Hybrid Assistive Limb) exoskeleton, have adapted to these requirements to maintain CE marking and market presence across the European Union.

Reimbursement remains a critical challenge and opportunity for the sector. In the U.S., the Centers for Medicare & Medicaid Services (CMS) has yet to establish a dedicated reimbursement code for exoskeleton-assisted therapy, resulting in variable coverage by private insurers and state Medicaid programs. However, there is growing momentum: in 2024, several regional payers began pilot programs to assess the cost-effectiveness of exoskeletons in post-stroke and spinal cord injury rehabilitation, with early data suggesting reduced long-term care costs and improved patient outcomes. Industry leaders such as Ekso Bionics and ReWalk Robotics are actively engaged in advocacy and evidence generation to support broader reimbursement.

In Europe and parts of Asia, reimbursement policies are similarly fragmented but trending positive. For example, Germany’s statutory health insurance has begun to reimburse exoskeleton therapy for certain indications, following successful clinical and economic evaluations. Japanese authorities, in collaboration with CYBERDYNE Inc., have also expanded coverage for robotic rehabilitation under national health insurance schemes.

Looking ahead, the next few years are expected to bring further harmonization of regulatory standards and incremental progress in reimbursement, driven by accumulating clinical evidence and advocacy from manufacturers and patient groups. As exoskeleton technology matures and demonstrates clear value in rehabilitation, broader and more consistent coverage is anticipated, potentially accelerating adoption in both hospital and outpatient settings.

Adoption Drivers: Patient Outcomes, Therapist Perspectives, and Cost-Benefit Analysis

Exoskeleton-assisted physical therapy systems are gaining traction in rehabilitation settings, driven by a convergence of clinical outcomes, therapist acceptance, and evolving cost-benefit dynamics. As of 2025, these systems are increasingly integrated into neurorehabilitation and orthopedic recovery programs, particularly for patients with spinal cord injuries, stroke, and lower limb impairments.

Clinical studies and real-world deployments have demonstrated that exoskeletons can enhance patient outcomes by enabling intensive, repetitive, and task-specific gait training. Devices such as the Ekso Bionics EksoNR and ReWalk Robotics ReWalk Personal 6.0 are designed to facilitate overground walking, which is associated with improved neuroplasticity and functional recovery compared to conventional therapy alone. Recent data from rehabilitation centers indicate that patients using exoskeletons often achieve earlier ambulation milestones and report higher engagement and motivation during therapy sessions.

Therapist perspectives are a critical driver of adoption. Initially, concerns centered on device complexity and workflow disruption. However, ongoing improvements in user interfaces, safety features, and training protocols have led to broader acceptance among clinicians. Companies like CYBERDYNE Inc., with its HAL (Hybrid Assistive Limb) system, have focused on intuitive controls and real-time feedback, allowing therapists to tailor therapy intensity and monitor patient progress efficiently. Furthermore, exoskeletons can reduce the physical burden on therapists by supporting patient weight and movement, potentially lowering the risk of occupational injuries.

Cost-benefit analysis remains a pivotal consideration for healthcare providers. While the initial investment in exoskeleton systems can be substantial, the potential for reduced length of stay, fewer secondary complications, and improved long-term independence for patients is increasingly recognized. Some manufacturers, such as Ottobock, are exploring flexible leasing and service models to lower financial barriers for clinics. Additionally, as device volumes grow and technology matures, unit costs are expected to decrease over the next few years, further improving the economic case for adoption.

Looking ahead, the outlook for exoskeleton-assisted therapy is positive. Ongoing clinical trials, expanding insurance coverage in select markets, and the integration of data analytics for personalized rehabilitation are expected to accelerate adoption. As more robust evidence accumulates and device usability continues to improve, exoskeletons are poised to become a standard adjunct in physical therapy, offering tangible benefits for patients, therapists, and healthcare systems alike.

Challenges: Technical, Clinical, and Market Barriers

Exoskeleton-assisted physical therapy systems have made significant strides in recent years, but several challenges persist as the sector moves through 2025 and into the near future. These barriers span technical, clinical, and market domains, each influencing the pace and breadth of adoption in rehabilitation settings.

Technical Challenges: Despite advances in robotics and sensor technology, exoskeletons still face hurdles related to device weight, battery life, and adaptability. Many current systems, such as those developed by ReWalk Robotics and Ekso Bionics, have improved portability and ergonomics, but further miniaturization and energy efficiency are needed for widespread daily use. Achieving seamless human-machine interaction remains complex, particularly in adapting to the unique gait patterns and needs of individual patients. Additionally, integration with real-time data analytics and tele-rehabilitation platforms is still evolving, with interoperability between devices and electronic health records (EHRs) posing ongoing technical obstacles.

Clinical Barriers: Clinically, robust evidence supporting the long-term efficacy and safety of exoskeleton-assisted therapy is still being established. While early studies and pilot programs have shown promise in improving mobility and functional outcomes for patients with spinal cord injuries and stroke, large-scale, multi-center trials are limited. Regulatory pathways, such as those overseen by the U.S. Food and Drug Administration (FDA), require comprehensive data, which can delay market entry and clinical adoption. Furthermore, training requirements for therapists and patients are significant, as highlighted by Ottobock, a major player in the field, which emphasizes the need for specialized certification and ongoing support to ensure safe and effective use.

Market Barriers: The high cost of exoskeleton systems remains a primary barrier to broader adoption. Devices from leading manufacturers like CYBERDYNE Inc. and Hocoma can cost tens of thousands of dollars, limiting accessibility for smaller clinics and individual users. Reimbursement policies are inconsistent across regions, with many insurers hesitant to cover these devices due to limited long-term outcome data. Additionally, the market is fragmented, with a mix of established companies and startups, leading to variability in device quality, support, and service infrastructure.

Outlook: Over the next few years, addressing these challenges will be critical for the sector’s growth. Industry leaders are investing in R&D to enhance device usability and reduce costs, while collaborations with healthcare providers aim to generate stronger clinical evidence. As regulatory frameworks evolve and reimbursement models adapt, the exoskeleton-assisted physical therapy market is expected to gradually expand, though overcoming these technical, clinical, and market barriers will remain a central focus through 2025 and beyond.

Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets

The global landscape for exoskeleton-assisted physical therapy systems is rapidly evolving, with significant regional differences in adoption, regulatory frameworks, and market drivers. As of 2025, North America, Europe, and Asia-Pacific are the primary regions shaping the sector, while emerging markets are beginning to show notable activity.

North America remains at the forefront of exoskeleton-assisted rehabilitation, driven by robust healthcare infrastructure, high R&D investment, and favorable reimbursement policies. The United States, in particular, is home to leading manufacturers such as Ekso Bionics and ReWalk Robotics, both of which have received FDA clearances for their devices. The region is witnessing increased integration of exoskeletons in rehabilitation centers and Veterans Affairs hospitals, with ongoing clinical studies supporting efficacy in stroke and spinal cord injury recovery. Canada is also expanding its adoption, supported by public-private partnerships and pilot programs in major hospitals.

Europe is characterized by strong regulatory oversight and a growing emphasis on assistive technologies for aging populations. The European Union’s Medical Device Regulation (MDR) has set high standards for safety and performance, influencing the development and deployment of exoskeletons. Companies such as Hocoma (Switzerland) and CYBERDYNE (with a European presence) are active in the region, supplying advanced robotic rehabilitation systems to clinics and research institutions. Germany, France, and the UK are leading adopters, with national health systems increasingly piloting exoskeletons for post-stroke and neurorehabilitation therapies.

Asia-Pacific is experiencing rapid growth, fueled by rising healthcare investments, government initiatives, and a large patient base requiring rehabilitation. Japan is a pioneer, with CYBERDYNE’s HAL exoskeleton widely used in hospitals and rehabilitation centers. South Korea and China are also investing heavily, with local manufacturers entering the market and collaborations with academic institutions to validate clinical outcomes. Australia is emerging as a regional hub for clinical trials and early adoption, supported by its advanced healthcare system.

Emerging markets in Latin America, the Middle East, and parts of Southeast Asia are beginning to explore exoskeleton-assisted therapy, primarily through pilot projects and partnerships with global manufacturers. While adoption is currently limited by cost and infrastructure, increasing awareness and international collaborations are expected to drive gradual uptake over the next few years.

Looking ahead, regional disparities in reimbursement, regulatory approval, and clinical integration will continue to shape the pace and scale of exoskeleton adoption. However, ongoing technological advancements and cross-border partnerships are likely to accelerate global access to exoskeleton-assisted physical therapy systems through 2025 and beyond.

Future Outlook: Next-Gen Exoskeletons, Partnerships, and Strategic Opportunities

The landscape for exoskeleton-assisted physical therapy systems is poised for significant transformation in 2025 and the years immediately following, driven by rapid technological advancements, strategic partnerships, and expanding clinical adoption. Exoskeletons, once primarily associated with industrial or military applications, are now increasingly integrated into rehabilitation settings to assist patients recovering from neurological injuries, stroke, or musculoskeletal disorders.

Key industry players are accelerating innovation in both hardware and software. Ekso Bionics, a pioneer in medical exoskeletons, continues to refine its EksoNR platform, which is FDA-cleared for use with patients suffering from acquired brain injury, stroke, and spinal cord injury. The company is focusing on enhancing device intelligence, real-time feedback, and data analytics to personalize therapy and improve patient outcomes. Similarly, ReWalk Robotics is advancing its ReStore soft exosuit, targeting gait training for stroke survivors, and is expected to expand its clinical footprint in North America and Europe through new distribution agreements and hospital partnerships.

In Asia, CYBERDYNE Inc. is expanding the deployment of its HAL (Hybrid Assistive Limb) exoskeleton in rehabilitation centers, leveraging AI-driven motion analysis to optimize therapy protocols. The company is also collaborating with academic and medical institutions to validate long-term efficacy and explore new indications, such as pediatric rehabilitation and degenerative diseases.

Strategic partnerships are a defining trend for 2025 and beyond. Device manufacturers are increasingly collaborating with hospital networks, insurance providers, and digital health platforms to integrate exoskeletons into broader care pathways. For example, Ottobock, a global leader in prosthetics and orthotics, is investing in exoskeleton R&D and forging alliances with rehabilitation clinics to accelerate clinical trials and gather real-world evidence. These partnerships are expected to facilitate regulatory approvals, reimbursement, and large-scale adoption.

Looking ahead, the next generation of exoskeletons will likely feature lighter materials, improved ergonomics, and enhanced connectivity for remote monitoring and tele-rehabilitation. Integration with wearable sensors and cloud-based analytics will enable therapists to track progress and adjust treatment plans dynamically. As costs decrease and clinical evidence mounts, exoskeleton-assisted therapy is anticipated to become a standard component of neurorehabilitation and orthopedic recovery programs worldwide, with leading companies such as Ekso Bionics, ReWalk Robotics, CYBERDYNE Inc., and Ottobock shaping the future of this transformative sector.

Sources & References

Physical therapist helping a Stroke Patient walk

Dafne Lajer

Dafne Lajer is a seasoned technology and fintech writer with a passion for exploring the intersection of innovation and finance. With a Bachelor’s degree in Computer Science from Stanford University, Dafne has developed a strong foundation in the principles of technology that underpin modern financial systems. Her extensive professional experience includes a pivotal role at Xypher Technologies, where she contributed to cutting-edge projects focused on blockchain integration and digital payment solutions. Through her insightful articles and in-depth research, Dafne aims to demystify complex technological concepts for a broader audience, empowering readers to navigate the rapidly evolving landscape of financial technology.

Leave a Reply

Your email address will not be published.

Don't Miss

Rising Star Ai Ogura Ignites New Era in MotoGP: A Thrilling Debut at Buriram

Rising Star Ai Ogura Ignites New Era in MotoGP: A Thrilling Debut at Buriram

Ai Ogura’s debut in MotoGP was groundbreaking, captivating audiences with
Achr Stock Price Soars! Is It the Future of Urban Transport?

Achr Stock Price Soars! Is It the Future of Urban Transport?

Archer Aviation is leading the charge in sustainable air mobility